MNCs for Bone Marrow Failure After Malignant Diseases Children Chemotherapy
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This project aims to investigate the therapeutic and repair effects of cord blood mononuclear
cells (MNCs) on bone marrow failure after chemotherapy in children with malignant diseases.
It is planned to collect 20 malignant children with bone marrow failure after chemotherapy
and randomly divide them into two groups. The umbilical cord blood mononuclear cells were
injected, ≥1×10^8 per infusion, once a week, and the recovery time of peripheral blood
leukocytes, neutrophils, platelets and hemoglobin was observed. According to the recovery of
myelosuppression, stop when the peripheral blood reaches leukocytes>1×10^9/L,
neutrophils>0.5×10^9/L, platelets>25×10^9/L, and hemoglobin>60g/L at the same time. Use,
share 1-4 times.
Statistical software was used to compare the changes of peripheral blood leukocytes,
neutrophils, platelets and hemoglobin before the start of the test (0d) and 1d, 3d, 5d, 7d,
10d, and 14d after the start of the test, as well as the severity of concurrent infections
and antibiotic use Time, number of infusions of blood products.